3480 Peachtree Road NE
Second Floor, Suite 103
Atlanta, GA 30326
United States
844 722 6333
https://www.alzamend.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 4
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Stephan Jackman | CEO & Director | 434,24k | S.O. | 1977 |
Mr. David J. Katzoff | Chief Financial Officer | 116,67k | S.O. | 1963 |
Mr. Milton Charles Ault III | Founder & Vice Chairman | S.O. | S.O. | 1970 |
Mr. Henry C. W. Nisser Esq. | Executive VP, General Counsel & Director | 50k | S.O. | 1969 |
Mr. Kenneth S. Cragun CPA | Senior Vice President of Finance | S.O. | S.O. | 1961 |
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
L’ISS Governance QualityScore de Alzamend Neuro, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..